Article

Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks.

Department of Pharmacy, Moses Cone Health System, Greensboro, NC 27710, USA.
Journal of Internal Medicine (Impact Factor: 5.79). 04/2007; 261(3):205-13. DOI: 10.1111/j.1365-2796.2006.01720.x
Source: PubMed

ABSTRACT The selective serotonin reuptake inhibitors (SSRIs) are extensively used for the treatment of multiple psychiatric conditions. In vitro and ex vivo data with these agents indicate they may have varying degrees of antiplatelet activity via multiple receptors. Reports of bleeding in patients receiving SSRIs appeared soon after their introduction. A review of the literature suggests SSRI therapy may increase the risk of bleeding especially with concomitant aspirin or nonsteroidal anti-inflammatory agents. Clinicians should exercise caution when prescribing these agents in high risk patients and maintain awareness of the potential contribution of SSRIs to unexplained bleeding episodes.

0 Bookmarks
 · 
55 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cervical interlaminar epidural steroid injections (ESIs) are commonly performed as one part of a multi-modal analgesic regimen in the management of upper extremity radicular pain. Spinal epidural hematoma (SEH) is a rare complication with a reported incidence ranging from 1.38 in 10,000 to 1 in 190,000 epidurals. Current American Society of Regional Anesthesia (ASRA), American Society of Interventional Pain Physicians (ASIPP), and the International Spine Intervention Society (ISIS) recommendations are that non-steroidal anti-inflammatory drugs (NSAIDs) do not need to be withheld prior to epidural anesthesia. We report a case wherein intramuscular ketorolac and oral fluoxetine contributed to a SEH and tetraplegia following a cervical interlaminar (ESI). A 66 year-old woman with chronic renal insufficiency and neck pain radiating into her right upper extremity presented for evaluation and was deemed an appropriate CESI candidate. Cervical magnetic resonance imaging (MRI) revealed multi-level neuroforaminal stenosis and degenerative intervertebral discs. Utilizing a loss of resistance to saline technique, an 18-gauge Tuohy-type needle entered the epidural space at C6-7. After negative aspiration, 4 mL of saline with 80 mg of methyl-prednisolone was injected. Immediately thereafter, the patient reported significant spasmodic-type localized neck pain with no neurologic status changes. A decision was made to administer 30 mg intramuscular ketorolac as treatment for the spasmodic-type pain. En route home, she developed a sudden onset of acute tetraplegia. She was brought to the emergency department for evaluation including platelet and coagulation studies which were normal. MRI demonstrated an epidural hematoma extending from C5 to T7. She underwent a bilateral C5-T6 laminectomy with epidural hematoma evacuation and was discharged to an acute inpatient rehabilitation hospital. Chronic renal insufficiency, spinal stenosis, female gender, and increasing age have been identified as risk factors for SEH following epidural anesthesia. In the present case, it is postulated that after the spinal vascular system was penetrated, hemostasis was compromised by the combined antiplatelet effects of ketorolac, fluoxetine, fish oil, and vitamin E. Although generally well tolerated, the role of ketorolac, a potent anti-platelet medication used for pain relief in the peri-neuraxial intervention period, should be seriously scrutinized when other analgesic options are readily available. Although the increased risk of bleeding for the alternative medications are minimal, they are nevertheless well documented. Additionally, their additive impairment on hemostasis has not been well characterized. Withholding NSAIDs, fluoxetine, fish oil, and vitamin E in the peri-procedural period is relatively low risk and should be considered for all patients with multiple risk factors for SEH.
    Pain physician 05/2014; 17(3):E385-95. · 4.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Depression is the most common psychiatric disease, which is treated by the use of antidepressive agents possessing various mechanisms of action. Thus, the use in preoperative period of antidepressive agents is frequent (7% of patients scheduled for surgery). The objective of this review was to update the knowledge on the drug interactions between antidepressive agents and drugs used in perioperative period.
    Annales Françaises d Anesthésie et de Réanimation 11/2011; 30(11):828-840. DOI:10.1016/j.annfar.2011.07.012 · 0.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Serotonergic antidepressants (SAds) are known to increase bleeding events, with a number of recent studies investigating this risk in surgical settings. Our main objective was to synthesize the current evidence to evaluate the clinical importance of SAd-related bleeding risk in the perioperative period. Methods: A systematic review of MEDLINE, Embase and PsychINFO until November 2013 was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. We examined the risk of perioperative bleeding adverse events in SAd users in comparison to controls. Results: A total of 13 relevant studies were identified across a broad variety of surgical procedures. SAds were associated with an increased risk of perioperative bleeding (odds ratios [ORs] = 1.21 - 4.14) and blood transfusions (ORs = 0.93 - 3.71). Conclusions: SAds are associated with increased perioperative bleeding events, particularly abnormal bleeding and blood transfusions. From a clinical perspective, the potential bleeding risks of SAds in surgical settings need to be carefully weighed against their psychiatric benefits. Future research will need to investigate potential strategies to mitigate SAd-related bleeding risk in the surgical context.
    Expert Opinion on Drug Safety 04/2014; 13(6). DOI:10.1517/14740338.2014.908182 · 2.74 Impact Factor

Preview

Download
0 Downloads